This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • Revascularization  • Thrombolysis  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Drug Therapy  • Adverse Effects  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Primary Results of the SYNERGY Randomized Trial

SYNERGY Trial Investigators

JAMA. 2004;292:45-54.

Context  Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non–ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy.

Objectives  To compare the outcomes of patients treated with enoxaparin vs unfractionated heparin and to define the role of enoxaparin in patients with non–ST-segment elevation ACS at high risk for ischemic cardiac complications managed with an early invasive approach.

Design, Setting, and Participants  The Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial was a prospective, randomized, open-label, multicenter, international trial conducted between August 2001 and December 2003. A total of 10 027 high-risk patients with non–ST-segment elevation ACS to be treated with an intended early invasive strategy were recruited.

Interventions  Subcutaneous enoxaparin (n = 4993) or intravenous unfractionated heparin (n = 4985) was to be administered immediately after enrollment and continued until the patient required no further anticoagulation, as judged by the treating physician.

Main Outcome Measures  The primary efficacy outcome was the composite clinical end point of all-cause death or nonfatal myocardial infarction during the first 30 days after randomization. The primary safety outcome was major bleeding or stroke.

Results  The primary end point occurred in 14.0% (696/4993) of patients assigned to enoxaparin and 14.5% (722/4985) of patients assigned to unfractionated heparin (odds ratio [OR], 0.96; 95% confidence interval [CI], 0.86-1.06). No differences in ischemic events during percutaneous coronary intervention (PCI) were observed between enoxaparin and unfractionated heparin groups, respectively, including similar rates of abrupt closure (31/2321 [1.3%] vs 40/2364 [1.7%]), threatened abrupt closure (25/2321 [1.1%] vs 24/2363 [1.0%]), unsuccessful PCI (81/2281 [3.6%] vs 79/2328 [3.4%]), or emergency coronary artery bypass graft surgery (6/2323 [0.3%] vs 8/2363 [0.3%]). More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9.1% vs 7.6%, P = .008) but nonsignificant excess in GUSTO (Global Utilization of Streptokinase and t-PA for Occluded Arteries) severe bleeding (2.7% vs 2.2%, P = .08) and transfusions (17.0% vs 16.0%, P = .16).

Conclusions  Enoxaparin was not superior to unfractionated heparin but was noninferior for the treatment of high-risk patients with non–ST-segment elevation ACS. Enoxaparin is a safe and effective alternative to unfractionated heparin and the advantages of convenience should be balanced with the modest excess of major bleeding.

Authors are members of the Executive and Steering committees of the SYNERGY Trial.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome
Michael Pedrini, Frank Hartig, and Christoph Pechlaner
JAMA. 2004;292(16):1952.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Fractionating Heparins and Their Clinical Trial Data—Something for Everyone
Pranab Das and David J. Moliterno
JAMA. 2004;292(1):101-103.
EXTRACT | FULL TEXT  

Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial
Michael A. Blazing, James A. de Lemos, Harvey D. White, Keith A. A. Fox, Freek W. A. Verheugt, Diego Ardissino, Peter M. DiBattiste, Joanne Palmisano, David W. Bilheimer, Steven M. Snapinn, Karen E. Ramsey, Laura H. Gardner, Vic Hasselblad, Marc A. Pfeffer, Eldrin F. Lewis, Eugene Braunwald, Robert M. Califf, and for the A to Z Investigators
JAMA. 2004;292(1):55-64.
ABSTRACT | FULL TEXT  

Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview
John L. Petersen, Kenneth W. Mahaffey, Vic Hasselblad, Elliott M. Antman, Marc Cohen, Shaun G. Goodman, Anatoly Langer, Michael A. Blazing, Anne Le-Moigne-Amrani, James A. de Lemos, Christopher C. Nessel, Robert A. Harrington, James J. Ferguson, Eugene Braunwald, and Robert M. Califf
JAMA. 2004;292(1):89-96.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential survival gains in the treatment of myocardial infarction
Chew et al.
Heart 2009;95:1844-1850.
ABSTRACT | FULL TEXT  

Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar and Cannon
Mayo Clin Proc. 2009;84:917-938.
ABSTRACT | FULL TEXT  

Antithrombotics in acute coronary syndromes.
Bonaca et al.
J Am Coll Cardiol 2009;54:969-984.
ABSTRACT | FULL TEXT  

Immediate vs Delayed Intervention for Acute Coronary Syndromes: A Randomized Clinical Trial
Montalescot et al.
JAMA 2009;302:947-954.
ABSTRACT | FULL TEXT  

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
Jolly et al.
J Am Coll Cardiol 2009;54:468-476.
ABSTRACT | FULL TEXT  

New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Van de Werf
Eur Heart J 2009;30:1695-1702.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Nutescu et al.
The Annals of Pharmacotherapy 2009;43:1064-1083.
ABSTRACT | FULL TEXT  

Does 'SWITCHing' from heparin to bivalirudin monotherapy result in a bleeding benefit?
Astroulakis and Hill
Eur Heart J Suppl 2009;11:C13-C18.
ABSTRACT | FULL TEXT  

Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Ebrahimi et al.
J Am Coll Cardiol 2009;53:1965-1972.
ABSTRACT | FULL TEXT  

Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score
Subherwal et al.
Circulation 2009;119:1873-1882.
ABSTRACT | FULL TEXT  

Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Potsis et al.
ANGIOLOGY 2009;60:148-158.
ABSTRACT  

Cost-Effectiveness Analysis of Anticoagulation Strategies in Non-ST-Elevation Acute Coronary Syndromes
Maxwell et al.
The Annals of Pharmacotherapy 2009;43:586-595.
ABSTRACT | FULL TEXT  

Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Lopes et al.
J Am Coll Cardiol 2009;53:1021-1030.
ABSTRACT | FULL TEXT  

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes
Budaj et al.
Eur Heart J 2009;30:655-661.
ABSTRACT | FULL TEXT  

Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias
Hirsch et al.
Eur Heart J 2009;30:645-654.
ABSTRACT | FULL TEXT  

Novel Multi-Modal Strategies to Promote Brain and Spinal Cord Injury Recovery
Ratan and Noble
Stroke 2009;40:S130-S132.
ABSTRACT | FULL TEXT  

Acute Coronary Syndromes
Hollenberg
ACCP Crit Care Med Brd Rev 2009;20:129-144.
FULL TEXT  

Bleeding during percutaneous intervention: tailoring the approach to minimise risk
Kinnaird et al.
Heart 2009;95:15-19.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding
Wang et al.
Circulation 2008;118:2139-2145.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White et al.
J Am Coll Cardiol 2008;52:807-814.
ABSTRACT | FULL TEXT  

Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting
Manzano-Fernandez et al.
Chest 2008;134:559-567.
ABSTRACT | FULL TEXT  

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
Lopes et al.
Eur Heart J 2008;29:1827-1833.
ABSTRACT | FULL TEXT  

Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease
Chan et al.
J Am Coll Cardiol Intv 2008;1:369-378.
ABSTRACT | FULL TEXT  

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome
Dobesh et al.
Am J Health Syst Pharm 2008;65:S22-S28.
ABSTRACT | FULL TEXT  

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
Lopes et al.
Heart 2008;94:867-873.
ABSTRACT | FULL TEXT  

2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Coons and Battistone
The Annals of Pharmacotherapy 2008;42:989-1001.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT | FULL TEXT  

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents
Crowther and Warkentin
Blood 2008;111:4871-4879.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White et al.
J Am Coll Cardiol 2008;51:1734-1741.
ABSTRACT | FULL TEXT  

Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes
Mehta
Eur Heart J Suppl 2008;10:C14-C21.
ABSTRACT | FULL TEXT  

Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
Montalescot et al.
Eur Heart J 2008;29:462-471.
ABSTRACT | FULL TEXT  

Myocardial Revascularization with Percutaneous Devices
Wilson and Willerson
Card Surg Adult 2008;3:573-598.
FULL TEXT  

Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials
Dumaine et al.
Arch Intern Med 2007;167:2423-2430.
ABSTRACT | FULL TEXT  

Evaluating the Optimal Timing of Angiography: Landmark or off the Mark?
Normand
Circulation 2007;116:2656-2657.
FULL TEXT  

Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non ST-Segment Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial
Tricoci et al.
Circulation 2007;116:2669-2677.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial
Mehta et al.
J Am Coll Cardiol 2007;50:1742-1751.
ABSTRACT | FULL TEXT  

Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndromes
Fox et al.
ANN INTERN MED 2007;147:304-310.
ABSTRACT | FULL TEXT  

Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Murphy et al.
Eur Heart J 2007;28:2077-2086.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
Nikolsky et al.
Eur Heart J 2007;28:1936-1945.
ABSTRACT | FULL TEXT  

Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes
LaPointe et al.
Arch Intern Med 2007;167:1539-1544.
ABSTRACT | FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM-TIMI-32 Trial
Giugliano et al.
J Am Coll Cardiol 2007;49:2398-2407.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial
Gibson et al.
J Am Coll Cardiol 2007;49:2238-2246.
ABSTRACT | FULL TEXT  

Managing acute coronary syndrome: Evidence-based approaches
Spinler
Am J Health Syst Pharm 2007;64:S14-S24.
ABSTRACT | FULL TEXT  

Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2549-2569.
ABSTRACT | FULL TEXT  

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Rao et al.
Eur Heart J 2007;28:1193-1204.
ABSTRACT | FULL TEXT  

Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
Miller et al.
Eur Heart J 2007;28:1079-1084.
ABSTRACT | FULL TEXT  

High-risk acute coronary syndrome patient and cardiac biomarkers in the emergency department: where do we stand?
Bagwe et al.
Eur Heart J 2007;28:1043-1044.
FULL TEXT  

Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT  

Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial
Stone et al.
JAMA 2007;297:591-602.
ABSTRACT | FULL TEXT  

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions
Mahaffey and Harrington
JAMA 2007;297:636-639.
FULL TEXT  

Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
Mahaffey et al.
Eur Heart J 2007;28:425-432.
ABSTRACT | FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Dzau et al.
Circulation 2006;114:2871-2891.
FULL TEXT  

Bivalirudin for Patients with Acute Coronary Syndromes.
Stone et al.
NEJM 2006;355:2203-2216.
ABSTRACT | FULL TEXT  

A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial: Enoxaparin Versus Unfractionated Heparin in Non-ST-Segment Elevation Acute Coronary Syndromes
Cohen et al.
J Am Coll Cardiol 2006;48:1346-1354.
ABSTRACT | FULL TEXT  

Bleeding and management of bleeding
Eikelboom and Hirsh
Eur Heart J Suppl 2006;8:G38-G45.
ABSTRACT | FULL TEXT  

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot et al.
NEJM 2006;355:1006-1017.
ABSTRACT | FULL TEXT  

Risk of bleeding after elective percutaneous coronary intervention.
O'Neill
NEJM 2006;355:1058-1060.
FULL TEXT  

Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul and Diamond
ANN INTERN MED 2006;145:62-69.
ABSTRACT | FULL TEXT  

Fondaparinux versus enoxaparin in acute coronary syndromes.
Majure et al.
NEJM 2006;354:2829-2829.
FULL TEXT  

A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial
Gibson et al.
J Am Coll Cardiol 2006;47:2364-2373.
ABSTRACT | FULL TEXT  

Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
Bailey and Steinhubl
CMAJ 2006;174:1431-1432.
FULL TEXT  

Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
The Fifth Organization to Assess Strategies in Acu
NEJM 2006;354:1464-1476.
ABSTRACT | FULL TEXT  

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Kastrati et al.
JAMA 2006;295:1531-1538.
ABSTRACT | FULL TEXT  

Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?
Bavry and Lincoff
Circulation 2006;113:1638-1640.
FULL TEXT  

Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio et al.
JAMA 2006;295:1152-1160.
ABSTRACT | FULL TEXT  

A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes
Rao et al.
J Am Coll Cardiol 2006;47:809-816.
ABSTRACT | FULL TEXT  

Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study
Chiara et al.
Eur Heart J 2006;27:393-405.
ABSTRACT | FULL TEXT  

Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial
Sabatine et al.
Circulation 2005;112:3846-3854.
ABSTRACT | FULL TEXT  

Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Eikelboom et al.
Circulation 2005;112:3855-3867.
ABSTRACT | FULL TEXT  

Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation 2005;112:IV-89-IV-110.
FULL TEXT  

Part 5: Acute Coronary Syndromes
Circulation 2005;112:III-55-III-72.
FULL TEXT  

High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin: Outcomes at 6 Months and 1 Year in the SYNERGY Trial
Mahaffey et al.
JAMA 2005;294:2594-2600.
ABSTRACT | FULL TEXT  

Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
Collet et al.
Eur Heart J 2005;26:2285-2293.
ABSTRACT | FULL TEXT  

Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes
de Winter et al.
NEJM 2005;353:1095-1104.
ABSTRACT | FULL TEXT  

The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
Giugliano and Braunwald
J Am Coll Cardiol 2005;46:906-919.
FULL TEXT